EE344 Cost per Responder Associated with Bimekizumab Against Il-17A-Inhibitors in the Treatment of Axial Spondyloarthritis in Sweden

Dec 1, 2023, 00:00
10.1016/j.jval.2023.09.610
https://www.valueinhealthjournal.com/article/S1098-3015(23)03740-3/fulltext
Title : EE344 Cost per Responder Associated with Bimekizumab Against Il-17A-Inhibitors in the Treatment of Axial Spondyloarthritis in Sweden
Citation : https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(23)03740-3&doi=10.1016/j.jval.2023.09.610
First page :
Section Title :
Open access? : No
Section Order : 10099
Categories :
Tags :
Regions :
ViH Article Tags :